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Jacoba M. Spikman3, Teus van Laar1,2* and the PPNN Study GroupAbstract
Background: Parkinson’s Disease (PD) is a heterogeneous, progressive neurodegenerative disorder which is
characterized by a variety of motor and non-motor symptoms. To date, no disease modifying treatment for PD
exists. Here, the study protocol of the Dutch Parkinson Cohort (DUPARC) is described. DUPARC is a longitudinal
cohort study aimed at deeply phenotyping de novo PD patients who are treatment-naïve at baseline, to discover
and validate biomarkers for PD progression, subtypes and pathophysiology.
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Methods/design: DUPARC is a prospective cohort study in which 150 de novo PD subjects will be recruited
through a collaborative network of PD treating neurologists in the northern part of the Netherlands (Parkinson
Platform Northern Netherlands, PPNN). Participants will receive follow-up assessments after 1 year and 3 years, with
the intention of an extended follow-up with 3 year intervals. Subjects are extensively characterized to primarily
assess objectives within three major domains of PD: cognition, gastrointestinal function and vision. This includes
brain magnetic resonance imaging (MRI); brain cholinergic PET-imaging with fluoroethoxybenzovesamicol (FEOBV-
PET); brain dopaminergic PET-imaging with fluorodopa (FDOPA-PET); detailed neuropsychological assessments,
covering all cognitive domains; gut microbiome composition; intestinal wall permeability; optical coherence
tomography (OCT); genotyping; motor and non-motor symptoms; overall clinical status and lifestyle factors,
including a dietary assessment; storage of blood and feces for additional analyses of inflammation and metabolic
parameters. Since the start of the inclusion, at the end of 2017, over 100 PD subjects with a confirmed
dopaminergic deficit on FDOPA-PET have been included.
Discussion: DUPARC is the first study to combine data within, but not limited to, the non-motor domains of
cognition, gastrointestinal function and vision in PD subjects over time. As a de novo PD cohort, with treatment
naïve subjects at baseline, DUPARC provides a unique opportunity for biomarker discovery and validation without
the possible confounding influences of dopaminergic medication.
Trial registration: NCT04180865; registered retrospectively, November 28th 2019.
Keywords: Parkinson disease, Neurodegenerative diseases, Observational study, Longitudinal studies, Biomarkers,
Neuropsychology, Cognition, Gastrointestinal microbiome, Microbiota, OphthalmologyBackground
Parkinson’s disease (PD) is the second most prevalent
neurodegenerative disorder, affecting up to 1 in 100
adults over the age of 60 [1]. Despite its large societal
impact, the cause of PD remains elusive and only symp-
tomatic treatments exists that mainly targets the motor
symptomatology. In addition, the clinical diagnosis of
PD poses a clear diagnostic challenge and is rejected in
20% of the cases [2, 3]. Though PD is clinically defined
by motor symptoms resulting from dopaminergic neuro-
degeneration in the substantia nigra, non-motor symp-
toms are present in the majority of cases and often
precede the motor symptoms by years [4]. The constella-
tion of both motor and non-motor symptoms greatly
differs between PD subjects, making PD a heterogeneous
disorder in which different clinical subtypes might repre-
sent different etiologies [5, 6].
To advance our understanding of PD pathophysiology
and move towards disease modifying treatments, it is es-
sential to investigate PD as broad as possible, taking into
account its large clinical heterogeneity. For this purpose,
extensive clinical characterization and biomarker assess-
ments are required for adequate classification of PD sub-
types and associated prognostic and pathophysiological
markers. Ideally, studies designed to discover and valid-
ate biomarkers in PD should only include treatment-
naïve PD subjects at baseline, to avoid the possible con-
founding effect of dopaminergic medication. However,
such study cohorts are sparsely available.
This paper describes the study protocol of the DUtch
PARkinson Cohort (DUPARC), a single-center, prospective,longitudinal, observational, cohort study at the University
Medical Center Groningen (UMCG) of de novo PD subjects,
who are treatment-naïve at baseline. PD participants are ex-
tensively characterized with the aim to discover and validate
biomarkers for PD subtypes, progression and pathophysi-
ology. Though the endpoints assessed in the DUPARC study
allow for subject characterization across a wide variety of do-
mains, DUPARC focuses on three domains in particular,
representing the interests and expertise of our research
group: (1) cognition, (2) gastrointestinal function and (3)
vision.
Cognition
Cognitive dysfunction is a common non-motor symptom
in PD that greatly influences the quality of life of patients.
Mild cognitive impairment (PD-MCI) is already present in
25–30% of newly diagnosed patients and is considered an
important risk factor for the development of PD dementia
[7, 8]. The cognitive profile in PD is highly heterogeneous,
with multiple cognitive domains affected.
The underlying pathology of cognitive impairment in
PD is complex and includes the degeneration of multiple
neurotransmitter systems, of which the cholinergic sys-
tem is thought to be of particular importance [9–11]. In
vivo cholinergic imaging studies revealed cholinergic
deficits in PD patients compared to control subjects,
with the cholinergic loss being even more pronounced
in PD patients with dementia, suggesting a direct rela-
tionship between cholinergic denervation and cognitive
decline in PD [12–14]. However, these findings are
based on indirect Positron Emission Tomography (PET)
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though acetylcholinesterase is considered to be a reliable
target for cholinergic imaging, it is located both on pre-
and postsynaptic membranes, and also binds postsynap-
tically on non-cholinergic neurons [15, 16]. Recently, the
selective PET tracer [18F]Fluoroethoxybenzovesamicol
(FEOBV) was introduced and validated [17, 18]. This
tracer binds presynaptically to the vesicular acetylcholine
transporter and is a more sensitive and regional cholin-
ergic marker compared to the cholinesterase binding
tracers [17, 18].
Combining selective dopaminergic and cholinergic im-
aging with detailed neuropsychological assessment in a longi-
tudinal cohort of de novo, treatment-naïve PD patients,
provides the opportunity to explore the exact role of the cho-
linergic system in specific cognitive domains, to identify sen-
sitive biomarkers of cognitive decline, and explore future
therapeutic targets. We hypothesize that (1) in newly diag-
nosed, treatment-naïve PD patients, a significant proportion
of patients will show cognitive impairment related to re-
gional cortical and subcortical cholinergic denervation; (2)
baseline regional cholinergic denervation will be a predictor
of cognitive decline in PD over time.
Gastrointestinal function
Gastrointestinal dysfunction, in particular constipation,
is one of the earliest manifestations of PD and can occur
up to 20 years before diagnosis [19]. In concordance with
the symptomatology, alpha synuclein deposition in Lewy
bodies and neurites, the pathological hallmark of PD, are
also found in the Enteric Nervous System (ENS) of PD
cases [20, 21]. The alpha synucleinopathy is believed to
spread in a prion-like manner via the vagal nerve to the
brain [22]. Moreover, intestinal inflammation and an in-
creased intestinal wall permeability are found in PD [23].
Possible determinants of the enteric pathology in PD in-
clude gut microbiota, which were found to modulate the
synucleinopathy, neuroinflammation and motor symp-
tomatology in a rodent PD model [24].
Recently, 16 independent studies have shown that the
gut microbiota composition of PD patients is signifi-
cantly different from healthy age-matched controls (HC)
[25]. Interestingly, the gut microbiome changes in PD do
not match those in idiopathic constipation, despite the
high prevalence of constipation in PD [26]. So far, pub-
lished studies on gut microbiota composition in PD al-
most exclusively included dopamine-suppleted PD
patients, which is a significant confounder. Moreover,
subtype analyses within PD have been limited, in which
PD subjects with autonomic dysfunction, indicative of a
possible gut-first subtype, might be of particular interest
[27]. Therefore, to advance the development of gut
microbiota composition as a biomarker or possible
therapeutic target in PD, it is a requirement to establishthe gut microbiota composition of extensively character-
ized treatment-naïve PD patients.
We hypothesize that (1) gut microbiome composition
of treatment-naïve de novo PD subjects is different from
HC; (2) dopaminergic medication drives differential
abundance of gut microbial taxa independent of PD pro-
gression; (3) PD subjects with autonomic dysfunction,
indicative of a gut-first subtype, will show distinct gut
microbial signatures compared to other PD subjects; (4)
the gut microbiome changes in (constipated) PD sub-
jects will be different from the changes in idiopathic
constipation subjects; (5) the intestinal wall permeability
will be increased already in de novo PD subjects with
concomitant signs of intestinal inflammation.
Vision
PD presents with a broad range of visual system dys-
functions, including visual hallucinations and defects in
color vision, contrast sensitivity and visual fields [28–
32]. Along with visual symptoms, thinning of the retinal
nerve fiber layer can be assessed by optical coherence
tomography (OCT) and is observed in PD, including
thinning of the inner-plexiform and the ganglion cell
layer [33]. The pattern of retinal thinning and the per-
ipheral visual defects in PD bear resemblance with glau-
coma, a disorder with a pathophysiological and
epidemiological link with PD [34, 35]. Though retinal
thinning has been suggested as possible biomarker for
PD diagnosis, severity and progression [32, 36], our un-
derstanding of the visual system in PD, and the possible
link with pathologies such as glaucoma, is still limited.
Two studies have been published investigating the ret-
ina in de novo treatment-naive patients with OCT [37,
38], and reported statistically significant thinning of the
retinal nerve fiber layer and macular ganglion cell-inner
plexiform layer. In treated PD subjects, it has been
shown that dopaminergic treatment and other interven-
tions commonly applied in PD, such as deep brain
stimulation, can alleviate some of the visual symptoms
present in PD, but are also able to induce or worsen vis-
ual symptoms [30]. However, there is a lack of longitu-
dinal studies incorporating the effect of dopaminergic
treatment in PD. In order to understand the effects of
PD on visual function and retinal structure, including
the seemingly contradictory effects of PD medication,
there is a need for an in-depth ophthalmological assess-
ment in a longitudinal PD cohort, with data collection
before and after treatment initiation.
We hypothesize that (1) de novo PD patients will show
a specific pattern of retinal thinning, in particular affect-
ing the inner plexiform layer; (2) the retinal thinning
pattern of PD will be different from glaucoma, with ret-
inal changes focusing on the inner plexiform layer in
PD, contrary to the ganglion cell layer in glaucoma; (3)
Table 1 Objectives of the DUPARC cohort study
Overall aim
To discover and validate biomarkers for Parkinson’s disease (PD)
subtypes, progression and pathophysiology.
General
1. To combine clinical assessment of both motor and non-motor
symptoms with outcome measures across multiple domains, in-
cluding neuropsychology, gastroenterology and ophthalmology.
Cognition
2. To establish the relationship between cognitive impairment and
cholinergic innervation in treatment-naïve PD patients.
3. To determine the relationship between cognitive impairment
and dopaminergic innervation in treatment-naïve PD patients.
4. To investigate the progression of the cognitive profile of de
novo PD patients and determine the incidence of PD associated
mild cognitive impairment over time.
5. To identify potential biomarkers of longitudinal cognitive decline
within the brain neurotransmitter system.
6. To identify potential biomarkers of longitudinal cognitive decline
within the brain functional connectivity and white matter tracts
using functional MRI and diffusion tensor imaging.
Gastrointestinal function
7. To establish the gut microbiome composition of treatment-naïve
PD subjects compared to age- and sex-matched control subjects.
8. To determine the possible influence of dopaminergic medication
on gut microbiome composition in PD after 1 year of
dopaminergic medication use.
9. To determine the specificity of gut microbiome changes for PD
diagnosis by additionally correcting for possible confounders
other than dopaminergic medication, eg. dietary habits, presence
and severity of constipation, non-dopaminergic medication, dis-
ease history.
10. To identify potential biomarkers of PD within the gut
microbiome, ranging in complexity from the identification of key
microbes, suitable for rapid quantification, to complex microbial
fingerprints. Potential biomarkers of PD should be further
validated for their specificity compared to other neurological and
neurodegenerative disorders, as well as their robustness in other
PD microbiome studies.
11. To correlate changes in gut microbiome composition in PD to
specific PD subtypes in terms of clinical presentation, rate of
progression, genetic risk profile and/or imaging parameters.
12. To investigate the gut permeability of treatment-naïve PD sub-
jects through the assessment of fecal and serum markers, as well
as a urinary sugar excretion test.
Vision
13. To determine retinal cell layer thickness in treatment-naïve PD
subjects compared to age- and sex-matched control subjects.
14. To determine retinal cell layer thickness in treatment-naïve PD
subjects compared to age- and sex-matched glaucoma subjects.
15. To determine clinical correlates of structural retinal changes and
functional tests, including visual, motor, non-motor and neuro-
psychological scores.
16. To determine the effect of dopaminergic medication on retinal
layer thickness and visual function.
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The DUPARC study is a single center, prospective, ob-
servational study of 150 de novo PD patients who are
treatment naïve at baseline with follow-up after 1 year
and 3 years, with the intention of an extended follow-up
with three-year intervals. DUPARC is designed to assess
16 specific objectives with a focus on the domains of
cognition, gastrointestinal function and vision, with the
overarching aim to discover and validate biomarkers for
PD subtypes, progression and pathophysiology (Table 1).
Study population
In- and exclusion criteria
Inclusion criteria consist of PD diagnosis by a movement
disorders specialist according to Movement Disorder Soci-
ety Clinical Diagnostic Criteria for PD, with a confirmed
dopaminergic deficit by means of an 3,4-dihydroxy-6-18F-
fluoro-l-phenylalanine (18F-FDOPA) PET scan.
PD subjects who are unable to provide written informed
consent, who are unable to comply with study procedures,
who have exclusion criteria for Magnetic Resonance Imaging
(MRI), who have gastrointestinal exclusion criteria influen-
cing gut microbiome composition, or whose PD diagnosis is
rectified during follow-up, are excluded from the study co-
hort. A detailed overview of the applicable in- and exclusion
criteria is provided in Supplementary Table 1.
Recruitment strategy
Participants are recruited via Parkinson Platform North-
ern Netherlands (PPNN), a collaborative network of PD
treating neurologists in 13 medical centers in the northern
part of the Netherlands. PPNN serves a total of approxi-
mately 5000 PD patients, with an incidence of 400 newly
diagnosed PD patient within this network. Treatment-
naïve de novo PD subjects who are willing to participate
are referred to the University Medical Center Groningen
(UMCG) to assess the in- and exclusion criteria. After in-
clusion and completion of the baseline assessments, pa-
tients return to their treating neurologist to continue care
as usual, including the start with dopaminergic treatment.
Control cohorts
Though the complete DUPARC protocol solely concerns
de novo PD subjects, there is ample opportunity to in-
terpret the assessed endpoints relative to appropriate
control cohorts. Primarily, age- and sex-matched control
subjects are recruited separately to ensure identical as-
sessment techniques for the neuropsychological,
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representing the three main domains of the protocol. In
addition, appropriate control subjects for the ophthal-
mological assessments, including HC and over 1000
glaucoma patients, are available under a different IRB-
protocol in the UMCG. These all received the ophthal-
mological assessments, including retinal imaging, ac-
cording to the UMCG standard operating procedures,
using the same OCT machine, during overlapping periods,
to ensure maximal compatibility with the DUPARC data.
Complementary, the gut microbiome and genetic assess-
ments will be compared to control subjects from Life-
Lines, a three generation, population-based cohort study
concerning 167.000 participants from the same geograph-
ical area in the northern part of the Netherlands [39]. Of
these participants, biomaterials such as fecal samples and
blood samples have been collected in two large subcohorts
(n = 9.000 and n = 1.100) [40, 41]. In addition, 38.000 Life-
Lines participants, of a total of 53.000 participants of
whom genotype data is available, have received the same
genome-wide genetic assessment using the Illumina GSA-
MD chip. Genotype information will eventually become
available for all 167.000 LifeLines participants. To ensure
compatibility, the LifeLines standard operating proceduresFig. 1 Baseline recruitment and assessments from Q4 2017 to Q3 2020 of
network of PD treating neurologists Parkinson Platform Northern Netherlan
of a saliva sample for genetic screening; 1b. Assessments of gastrointestina
2. Participants visit the University Medical Center Groningen (UMCG) on 2 d
ophthalmological assessments; 2d. clinical assessments. * In a subset of par
samples and a urinary excretion test. ** Hyposmia is also assessed using thfor the gut microbiome and genetic analyses are also used
in DUPARC. Biomaterial from selected LifeLines partici-
pants can be reanalyzed to assess possible batch effects.
Moreover, stool frequency and consistency has been
assessed using the same stool diary in DUPARC and Life-
Lines, allowing for the identification of LifeLines subjects
with idiopathic constipation. Lastly, a large proportion of
endpoints, including the neuropsychological assessments,
will be assessed using norm-rated tools that depict the
performance of the patient as a percentile corrected for
relevant demographics, such as age and level of
education.
Study procedures
At baseline, study procedures start at home with the col-
lection of biomaterials for genetic screening and the
completion of gastroenterological assessments and vari-
ous other questionnaires. After the home assessments,
participants visit the UMCG during 2 days for PET and
MR-imaging, as well as a complete neuropsychological,
ophthalmological and clinical assessment. An overview
of the baseline assessments is depicted in Fig. 1.
Participants will receive follow-up assessments after 1
and 3 years, with the intention of an extended follow-uptreatment-naïve de novo PD subjects through the collaborative
ds (PPNN). 1. Study procedures start at home with 1a. the collection
l function and stool sample collection; 1c. questionnaire assessments.
ays for 2a. a complete cognitive assessment; 2b. imaging; 2c.
ticipants, intestinal wall permeability will also be assessed using blood
e Sniffin’ sticks. Source clipart: clipart-library.com
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visited at home for a repeated gastroenterological, clin-
ical and questionnaire assessment. During the three-year
follow-ups the complete baseline assessments are re-
peated with the exception of the genetic and gastrointes-
tinal assessments. All assessed endpoints and the time of
assessments are presented in Table 2.Data management
Data are stored in an electronic Case Report Form
(eCRF) using Castor, a Good Clinical Practice (GCP)
certified electronic Data Capture (EDC). Data unfit for
storage in the eCRF (eg. imaging and metagenomic data)
are stored on local secured servers at the UMCG. The
metadata are stored in the eCRF. Study monitoring will
be performed by in-house study monitors of the UMCG.
Depending on the type of data and associated privacy
regulations, data from the DUPARC project will be
made publicly available or will become available via the
corresponding author, upon reasonable request.Sample size
Since most objectives of the DUPARC cohort study con-
cern a first assessment in treatment-naïve de novo PD
subjects, a formal power calculation is hampered, as no
adequate estimation of the expected effect sizes can be
provided. However, the effect sizes previously reported
in already treated PD subjects with longer disease dur-
ation are mostly expected to be larger than the effect
sizes in our cohort. Therefore, a power calculation based
on previous reports will provide us with a minimum
number of participants to include, to assess the most im-
portant endpoints within the domains of cognition,
gastrointestinal function and vision.
The primary objective related to the cognitive domain
is to establish the relationship between cognitive impair-
ment and pre-synaptic cholinergic degeneration in de
novo PD patients. This will be analyzed using choliner-
gic PET-imaging with FEOBV in combination with
neuropsychological assessments covering all cognitive
domains, including complex attention, learning and
memory, executive function, perceptual-motor function,
language, and social cognition. Because of the novelty of
FEOBV, previous research using FEOBV-PET in PD is
limited. Significant results were found in a small group
comparing PD and control subjects [18]. Cross-sectional
comparisons between PD subgroups have included be-
tween 15 and 79 PD patients, with significant results
[42]. The size of the DUPARC cognition data is there-
fore expected to be sufficient for group and sub-group
analyses, as well as detailed correlational research on the
specific cognitive domains. Because of the great hetero-
geneity at baseline in both cognitive performance andcortical cholinergic innervation in PD, such a large co-
hort is needed for correlational analyses [43, 44].
The main objective within the gastrointestinal function
domain is the comparison of the gut microbiome com-
position with HC. Though a power calculation for meta-
genomic analyses is not possible, we think our sample
size will be sufficient to do these analyses, because previ-
ous studies already reported significant differences with
far smaller sample sizes varying between 10 and 72 in-
cluded PD subjects. Only two treatment-naïve subgroups
of 12 and 39 PD subjects have been investigated in pre-
vious studies, reporting fewer taxonomic differences in
the treatment-naïve group, compared to already treated
subjects. The DUPARC gut microbiome data therefore
surpasses most PD gut microbiome studies in sample
size, and is by far the largest treatment-naïve dataset,
allowing for more robust microbiome composition sig-
natures and correction for confounders.
Regarding the domain of vision, the most recent meta-
analysis on OCT imaging in PD has reported overall
mean effect sizes of 0.45 for several retinal cell layers,
comparing HC to PD subjects [33]. For a similar effect
size, with an alpha of 0.05, and a two-tailed comparison
of means, a sample size of 79 subjects for each group
would be sufficient to achieve a power of 0.80.
The sample size of 150 participants therefore clearly
surpasses the expected numbers needed to assess the
primary objectives within the key domains of DUPARC.
Nevertheless, a sample size of 150 participants is still ne-
cessary, as the anticipated effect sizes of various bio-
markers in treatment-naïve de novo PD subjects is
expected to be lower, compared to treated PD subjects
with longer disease duration. In addition, to find bio-
markers indicative of PD subtypes, the PD sample not only
has to provide both case and control samples for a subtype
comparison, but also the intergroup differences are expected
to be lower if PD subgroups are compared. Our sample size
of 150 participants will most likely allow for binary and trin-
ary subtype comparisons, given the aforementioned samples
sizes required to distinguish PD from HC. Lastly, the sample
size also needs to be larger than calculated to account for
participants who will be lost to follow-up. For this purpose,
180 participants will be included at baseline to account for
30 drop-outs and non-PD cases, in order to ensure a sample
size of 150 participants.
Statistical analysis
Relevant statistical analyses will be performed dependent
on the applicable objective as formulated in Table 1. Since
the various endpoints within and between domains could
be densely correlated, especially based on the hypothesis
that PD characteristics aggregate within distinctive PD
subtypes, the correlations of variables across domains will
be assessed [45]. Provided the extensiveness and
Table 2 Overview assessments DUPARC





Montreal cognitive assessment Cognitive screening X X X
Rey auditory verbal learning test Learning and memory X X
Location learning test Learning and memory X X
Wechsler Adult Intelligence Scale IV: Digit Span Learning and memory X X
Wisconsin card sorting test Executive functioning X X
Letterfluency Executive functioning X X
Hayling sentence completion test Executive functioning X X
Stroop color word test Complex attention X X
Trail making test Complex attention X X
Vienna Test System Reaction time test Complex attention X X
Boston naming test Language X X
Semantic Fluency Language X X
Test of everyday attention: Map search Perceptual-motor function X X
Judgment of line orientation Perceptual-motor function X X
Facial expression of emotion: Stimuli and tests Social cognition X X
Dutch adult reading test Premorbid intelligence X X
Vision
Farnsworth D15, Lanthony D15 Color vision X X
Optical Coherence Tomography Structural retinal imaging X X
HFA2 SITA Fast Peripheral vision X X
Pelli Robson Contrast Sensitivity Contrast sensitivity X X
Non-contact tonometry Intraocular pressure X X
Visual acuity Visual acuity X X
Gastrointestinal function
16S rRNA gene and metagenomic sequencing Fecal microbiome composition X X
Stool diary (7 days) Stool frequency and consistency X X
Dietary diary (3 days) Nutrient intake X X
Fecal calprotectin Intestinal wall permeability -
inflammation
X
Fecal alpha1-antitrypsin Intestinal wall permeability - protein
leakage
X
Serum zonulina Intestinal wall permeability - mucosal
barrier integrity
X
Urinary sugar excretion testa Intestinal wall permeability X
Serum LPSa Intestinal wall permeability - microbial
translocation
X
Other non-motor symptom assessment
Sniffin’ Sticks Hyposmia X X
Non Motor Symptom Questionnaire Non-motor symptoms screening X X X
REM Sleep Behavioral Disorder Questionnaire REM sleep behavioral disorder X X X
Hospital Anxiety and Depression Scale Anxiety and depression X X X
Dutch Multifactor Fatigue Scale Fatigue X X X
Apathy Evaluation Scale Apathy X X X
Questionnaire for Impulsive-Compulsive Disorder in Parkinson’s Impulsive-compulsive disorder X X X
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Table 2 Overview assessments DUPARC (Continued)






MDS-UPDRS III Motor functioning X X X
Hoehn & Yahr Disease severity X X X




MDS-UPDRS II Motor aspects of experiences of daily
living
X X X
Utrechtse coping lijst Coping X X X
Parkinson’s Disease Quality of Life Questionnaire 39 Quality of life X X X
Dysexecutive Questionnaire Dysexecutive syndrome X X X
Zarit Caregiver Burden inventory Caregiver burden X X X
General information
Disease History X X X
Demographics X X
Imaging
FDOPA PET Brain dopaminergic imaging X X
FEOBV PET Brain cholinergic imaging X X
MRI brain – Resting State X X
MRI brain – Diffusion Tensor Imaging X X
MRI brain – Arterial Spin Labeling X X
MRI brain – T1 X X
MRI brain – T2 X X
MRI brain - Susceptibility Weighted Imaging X X
Genetics
GSA-MD Genome-wide genotyping X
Blood samplesa
Plasma EDTA (8 × 2ml aliquots) X X
Serum (4 × 2ml aliquots) X X
Buffy coat (2x) X X
EDTA Ethylenediaminetetraacetic acid, FDOPA PET 18Fluor dopamine positron emission tomography, FEOBV PET 18Fluoroethoxybenzovesamicol positron emission
tomography, GSA-MD Illumina Infinium Global Screening Assay (MD variant), HFA2 SITA Fast Humphrey Field Analyzer 2 SITA 24–2 – Fast visual field perimetry, LPS
Lipopolysaccharide; MDS-UPDRS Movement Disorders Society Unified Parkinson’s Disease Rating Scale, MoCA Montreal Cognitive Assessment, MRI Magnetic
Resonance Imaging
aBlood withdrawal and urinary sugar excretion tests are performed in a subset of participants
Boertien et al. BMC Neurology          (2020) 20:245 Page 8 of 11complexity of the DUPARC dataset, advanced statistical
techniques, including artificial intelligence, will be used
for cross-domain analyses.
Ethics approval and consent to participate
DUPARC is conducted in accordance with the Dec-
laration of Helsinki and national and international
standards of GCP. Potential participants receive de-
tailed written and oral information on the study
procedures and all participants provide written in-
formed consent. Ethical approval of the studyprotocols was obtained from the Medical Ethics Re-
view Board of the University Medical Center Gro-
ningen (METc UMCG). The DUPARC study
protocol is registered at the Dutch Central Commit-
tee on Research Involving Human Subjects (CCMO)
with trial registration number NL60540.042.17,
whereas the microbiome study is registered separ-
ately with trial registration number NL61123.042.17.
In addition, the study has been registered retro-
spectively on November 28th 2019 at clinicaltrials.
gov, with identifier NCT04180865.
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The first visit of the first patient was performed in Q4
2017. Baseline inclusion is planned until Q3 2020, and is
on schedule. The milestone of 100 included PD subjects
with a confirmed dopaminergic deficit on FDOPA-PET
was reached in Q3 2019. The first publications on the
baseline data are expected in 2020, followed by the first
follow-up data in 2023.Discussion
DUPARC will be the first study to assess a variety of bio-
markers and associated endpoints, combining multiple im-
portant disease domains, including cognition, gastrointestinal
function, vision, neuroimaging and motor performance, in a
cohort of de novo PD subjects who are treatment naïve at
baseline. Therefore, DUPARC provides a unique opportunity
for biomarker discovery. Complementary, DUPARC can be
used to validate previous findings from existing cohort stud-
ies in a treatment-naïve PD cohort.
There is a large need for early markers of PD, its sub-
types and progression. First, disease-modifying interven-
tions should ideally be implemented as soon as possible
to slow down the course of the disease, highlighting the
need for a more accurate diagnosis of PD in the early
phases of the disease. Second, given the clinical and pos-
sible etiological heterogeneity of PD, adequate subject
stratification is imperative to advance our understanding
of the disease mechanisms and informs trial design for
putative disease-modifying trials. Third, the development
of disease-modifying therapies is hampered by the lack
of a solid measurement of disease progression. DUPARC
fulfills these needs, given the inclusion of early stage de
novo PD subjects, and the long-term follow-up with ex-
tensive assessment of endpoints in a variety of non-
motor and motor domains of PD. The included patients
in DUPARC are therefore very suitable for disease-
modifying trials.
Biomarker discovery in PD should ideally be per-
formed in treatment-naïve PD patients at baseline, since
this eliminates the possible confounding effects of dopa-
minergic medication that cannot adequately be corrected
for in a case-control setting. Causative inferences can be
summarized by three possible scenarios, in which the
biomarker is either causative for PD, caused by PD or is
a confounder. Therefore, biomarkers discovered in the
DUPARC treatment-naïve de novo PD cohort provide
promising leads for replication and validation in relevant
cohorts, and functional inquiry into the pathophysio-
logical significance of the biomarker and its potential as
a therapeutic target. Such validation studies might in-
clude PD cohorts enriched for a specific PD associated
genotype (eg. GBA1 mutations) or functional research
on patient derived biomaterial by reprogramming ofinduced pluripotent stem cells (eg. organ-on-a-chip, hu-
man intestinal organoids).
Additionally, DUPARC has an optimal design with its
single center set-up and the extensive assessment of
endpoints. Though participants are recruited from 13
medical centers, all study assessments are performed in
the UMCG or at home by UMCG investigators, accord-
ing to the same standard operating procedures. This al-
lows for the combined analysis of endpoints across
various domains, without possible confounding influ-
ences of interinstitutional and interrater variability. Next
to addressing the objectives of DUPARC as formulated
in Table 1, this cohort provides multiple opportunities
to combine endpoints across various domains, such as
gastrointestinal dysfunction and cholinergic denervation,
which will further advance our understanding of the dis-
ease mechanisms of PD and its subtypes.
Lastly, DUPARC can be used to validate the findings
of other cross-sectional or longitudinal PD cohorts.
Since most cohort studies concern already treated pa-
tients or lower numbers of treatment- naïve subjects,
validation of their results is required to disentangle the
putative confounding influence of dopaminergic medica-
tion from any PD related effects. A considerable overlap
can be observed with other cohort studies such as the
Personalized Parkinson Project and the Parkinson’s Pro-
gression Markers Initiative, giving ample opportunity for
cross-linking and validation of findings in our single-
center study cohort of treatment-naïve PD subjects. In
addition, the relation of more extensively studied do-
mains with relatively unique endpoints in DUPARC,
such as retinal layer scanning and cholinergic denerv-
ation, can be assessed.
In conclusion, DUPARC provides a unique opportunity
for biomarker discovery and validation for PD subtypes, pro-
gression and pathophysiology in a treatment-naïve de novo
PD cohort across multiple important disease domains.Supplementary information
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